drugset
drugset / Trial / NCT02979561

Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

NCT02979561 ↗

Phase 4 Unknown 200 enrolled Meshalkin Research Institute of Pathology of Circulation
RandomizedParallel-groupOpen-labelTreatment

Summary

A prospective randomised controlled study to evaluate outcomes of the treatment with pradaxa or warfarin for prevention of recurrent DVT in patients with angiographically confirmed acute massive pulmonary embolism undergoIng endovascular mechanical fragmentation and thrombolytic therapy. \[RE-SPIRE study\]

Timeline

Start
2016-10
Primary completion
2018-06
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg —
Comparator Warfarin Small molecule — —

Indications

No indication recorded.